Colocalization of basic fibroblast growth factor and CD44 isoforms containing the variably spliced exon v3 (CD44v3) in normal skin and in epidermal skin cancers

British Journal of Dermatology

Volumn 141, Issue 5, 1999, Pages 824-832

  Grimme, H U ^a   Termeer, C C ^a   Bennett, K L ^b   Weiss, J M ^a   Schopf E ^a   Aruffo, A ^b   Simon, Jan C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Basic fibroblast growth factor; CD44; CD44v3; Keratinocytes; Skin carcinogenesis

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; HEPARAN SULFATE; HEPARIN; HERMES ANTIGEN; N ACETYLGALACTOSAMINE 4 SULFATASE;

ARTICLE; BASAL CELL CARCINOMA; CELL CULTURE; CELL PROLIFERATION; CELL TRANSFORMATION; EPIDERMIS; EXON; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SKIN CANCER; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; TUMOR CELL;

ANTIGENS, CD44; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CELL CULTURE TECHNIQUES; CELL DIVISION; FIBROBLAST GROWTH FACTOR 2; HEPARITIN SULFATE; HUMANS; INFANT, NEWBORN; KERATINOCYTES; MALE; SKIN; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032711049     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1999.03154.x     Document Type: Article

References (39)

1. 1 Screaton GR, Bell MV, Jackson DG et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced cxons. Proc Natl Acad Sci USA 1992; 89: 12160-4.
2. 2 Herrlich PM, Zöller M, Pals ST, Ponta H. CD44 splice variants: metastases meet lymphocytes. Immunol Today 1993; 14: 395-9.
3. 3 Hirano H, Screaton GR, Bell MV, Hodes RJ. CD44 isoform expression mediated by alternative splicing: tissue-specific regulation in mice. Int Immunol 1994: 6: 49-59.
4. 4 Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv Immunol 1994; 54: 271-335.
5. 5 Sherman L, Sleeman J, Herrlich P, Ponta H. Hyaluronate receptors: key players in growth, differentiation, migration and tumour progression. Curr Opin Cell Biol 1994; 6: 726-33.
6. 6 Haggerty JG, Bretton RH, Milstone LM. Identification and characterization of a cell surface proteoglycan on keratinocytes. J Invest Dermatol 1992; 9: 374-80.
7. 7 Kaya G, Rodriguez I, Lorcano JL et al. Selective suppression of CD44 in keratinocytes of mice bearing an antisense CD44 transgene driven by a tissue-specific promotor disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation. Genes Dev 1997; 11: 996-1007.
8. 8 Simon JC. Heider KH, Dietrich A et al. Expression of CD44 isoforms in human skin cancer. Eur J Cancer 1996; 32A: 1394-400.
9. 9 Ichikawa T, Masumoto J, Kaneko M et al. Moesin and CD44 expression in cutaneous melanocytic tumours. Br J Dermatol 1998; 138: 763-8.
10. 10 Dietrich A, Tanczos E, Vanscheidt W et al. High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival. Eur J Cancer 1997; 33: 926-30.
11. 11 Dietrich A, Tanczos E, Vanscheidt W et al. Detection of CD44 splice variants in formalin-fixed, paraffin-embedded specimens of human skin cancer. J Cutan Pathol 1997; 24: 37-42.
12. 12 Harwood CA, Green MA, Cook MG. CD44 expression in melanocytic lesions: a marker of malignant progression? Br J Dermatol 1996; 135: 876-82.
13. 13 Seiter S, Tilgen W. Hermann K et al. Expression of CD44 splice variants in human skin and epidermal tumours, Virchows Arch 1996; 428; 141-9.
14. 14 Hardingham TE, Fosang AJ. Proteoglycans: many forms and many functions. FASEB J 1992; 6: 861-70.
15. 15 Kjellen L, Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem 1991; 60: 443-75.
16. 16 Tanaka Y, Adams DH, Hubscher S et al. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta. Nature 1993; 361: 79-82.
17. 17 Jackson DG, Bell JL, Dickinson R et al. Alternative splicing of an alternative exon v3 generates proteoglycan-like isoforms of the lymph node homing receptor CD44. J Cell Biol 1995; 128: 673-85.
18. 18 Bennett KL, Jackson DG, Simon JC et al. CD44 isoforms containing exon v3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 1995; 128: 687-98.
19. 19 Simon JC, Cruz PD, Bergstresser PR, Tigelaar RE. PMA-activated keratinocytes stimulate proliferation of resting peripheral blood mononuclear lymphocytes via a MHC-independent, but protein kinase C-, and ICAM-1 dependent mechanism. J Immunol 1991; 146: 476-84.
20. 20 Camp RL, Scheynius A, Johansson C, Pure E. CD44 is necessary for optimal contact allergic responses but is not required for normal leukocyte extravasation. J Exp Med 1993; 178: 497-507.
21. 21 O'Keefe EJ, Chiu ML, Payne RE. Stimulation of growth of keratinocytes by basic fibroblast growth factor. J Invest Dermatol 1988; 90: 767-9.
22. 22 Halaban K, Mocllmann G. Fibroblast growth factors. In: Epidermal Growth Factors and Cytokines (Luger TA, Schwarz T, eds). New York: Marcel Dekker. 1994: 273-89.
23. 23 Schulze-Osthoff K, Risau W, Vollmer E, Sorg C. In situ detection of basic fibroblast growth factor by highly specific antibodies. Am J Pathol 1990; 137: 85-92.
24. 24 Yamamoto N, Matsutani S, Yoshitake Y, Nishikawa K. Immunohistochemical localization of basic fibroblast growth factor in A431 epidermoid carcinoma cells. Histochemistry 1991; 96: 479-85.
25. 25 Herbold KW, Zhou J, Haggerty JG. Milstone LM. CD44 expression on epidermal melanocytes. J Invest Dermatol 1996; 106: 1230-5.
26. 26 Becker D, Meier CB, Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J 1989; 8: 3685-91.
27. 27 Bernfield M, Kokenyesi R, Kato M et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 1992; 8: 365-93.
28. 28 Flaumenhaft R, Moscatelli D, Saksela O, Rifkin DB. Role of extracellular matrix in the action of basic fibroblast growth factor: matrix as a source of growth factor for long-term stimulation of plasminogen activator production and DNA synthesis. J Cell Physiol 1989; 140: 75-81.
29. 29 Inki P, Joensu H, Grenman R et al. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br J Cancer 1994; 70: 319-23.
30. 30 Drake SL, Klein DJ, Mickelson DJ et al. Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived, heparin-binding synthetic peptide. J Cell Biol 1992; 117: 1331-41.
31. 31 Cohen IR, Murdoch AD, Naso MF et al. Abnormal expression of perlecan proteoglycan in metastatic melanomas. Cancer Res 1994; 54: 5771-4.
32. 32 Vlodavsky I, Korner G, Ishai-Michaeli R et al. Extracellular matrix-resident growth factors and enzymes: possible involvement in tumour metastasis and augiogenesis. Cancer Metast Rev 1990; 9: 203-26.
33. 33 Vigny M, Ollier-Hartmann MP, Lavigne M et al. Specific binding of basic fibroblast growth factor to basement membrane-like structures and to purified heparan sulfate protcoglycan of the EHS tumor. Cell Physiol 1988; 137: 231-8.
34. 34 Webb LM, Ehrengruber MU, Clark-Lewis I et al. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin-8. Proc Natl Acad Sci USA 1993; 90: 7158-62.
35. 35 Brown TA, Bouchard T, St John T et al. Human keratinocytes express a new CD44 core protein (CD44E) as a heparan-sulfate intrinsic membrane proteoglycan with additional exons. J Cell Biol 1991; 113; 207-21.
36. 36 Bashkin P, Doctrow S, Klagsbrun M et al. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 1989; 28: 1737-43.
37. 37 Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biolchem 1989; 58: 575-606.
38. 38 Cross M. Dexter TM. Growth factors in development, transformation and tumorigenesis. Cell 1991; 64: 271-80.
39. 39 Novotui E. Psoriasis treatment by heparin. Acta Universitatis Carol 1986; 32: 243-5.